Skip to main content

Advertisement

SpringerLink
Log in

Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen

  • 2004 Human Cell Society Award
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Prostate cancer cells express prostate-specific membrane antigen (PSMA). We developed an IgM type monoclonal antibody against PSMA. The antibody was coupled to poly-L-lysine and thereafter this conjugate was mixed with cationic liposomes containing plasmid DNA. The antibody-liposome complex was tested whether it could deliver the gene of interest selectively to the PSMA positive cells. As assessed by β-galactosidase reporter gene, the transfection efficiency was 13.2% with anti-PSMA-liposome complex as compared to 4% with control IgM liposome complex. In contrast., no such differences were observed in PSMA negative PC-3, DU145 and T24 cells. Furthermore, in the suicide gene therapy in vitro with thymidine base gene plus ganciclovir system, anti-PSMA liposome complex demonstrated a selective growth inhibitory effect on PSMA positive LNCaP cells but not on PSMA negative cell lines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ikegami S, Tadakuma T, Suzuki S, et al.: Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn. J. Cancer Res. 93: 1154–1163, 2002.

    Article  PubMed  CAS  Google Scholar 

  2. Ikegami S, Tadakuma T, Ono T, et al.: Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci. 95: 367–370, 2004

    Article  PubMed  CAS  Google Scholar 

  3. Israeli RS, Powell CT, Fair WR, et al.: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53: 227–230, 1993.

    PubMed  CAS  Google Scholar 

  4. Bostwick DG, Pacelli A, Blute M, et al.: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (Phila). 82: 2256–2261, 1998.

    Article  CAS  Google Scholar 

  5. Israeli RS, Powell CT, Corr JG, et al.: Expression of the prostate-specific membrane antigen. Cancer Res. 54: 1807–1811, 1994.

    PubMed  CAS  Google Scholar 

  6. Sweat SD, Pacelli A, Murphy GP, et al.: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52: 637–640, 1998.

    Article  PubMed  CAS  Google Scholar 

  7. Silver DA, Pellicer I, Fair WR, et al.: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3: 81–85, 1997.

    PubMed  CAS  Google Scholar 

  8. Chang SS, O’Keefe DS, Bacich DJ, et al.: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 5: 2674–2681, 1999.

    PubMed  CAS  Google Scholar 

  9. Kawasaki M and Nakayama J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57: 2321–2324, 1997.

    Google Scholar 

  10. Wright GL Jr., Grob BM, Haley C, et al.: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326–334, 1996.

    Article  PubMed  Google Scholar 

  11. Hashimoto Y, Sugawara M, Endoh H, et al.: Coating of liposomes with subunits of monoclonal IgM antibody and targeting of liposomes. J. Immuno. Methods. 62: 155–162, 1983.

    Article  CAS  Google Scholar 

  12. Wagner E, Zenke M, Cotten M, et al.: Transferrinpolycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA, 87: 3410–3414, 1990.

    Article  PubMed  CAS  Google Scholar 

  13. Zhu ZB, Makhija SK, Lu B, et al.: Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther. 11: 645–648, 2004.

    Article  PubMed  CAS  Google Scholar 

  14. Latham JP, Searle PF, Mautner V, et al.: Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 60: 334–341, 2000.

    PubMed  CAS  Google Scholar 

  15. Lehrman S: Virus treatment questioned after gene therapy death. Nature. 401: 517–518, 1999.

    Article  PubMed  CAS  Google Scholar 

  16. Yoon SK, Mohr L, O’Riordan CR, et al.: Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate. Biochem. Biophys. Res. Commun. 272: 497–504, 2000.

    Article  PubMed  CAS  Google Scholar 

  17. Volpers C, Thirion C, Biermann V, et al.: Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J. Virol. 77: 2093–2104, 2003.

    Article  PubMed  CAS  Google Scholar 

  18. Matar P, Rojo F, Cassia R, et al.: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10: 6487–6501, 2004.

    Article  PubMed  CAS  Google Scholar 

  19. Bocci G, Man S, Green SK, et al.: Increased plasma vascular endothelid growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 64: 6616–6625, 2004.

    Article  PubMed  CAS  Google Scholar 

  20. Leonard JP, Coleman M, Ketas JC, et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial results. Clin. Cancer Res. 10: 5327–5334, 2004.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, National Defense Medical College, Japan

    Shusei Ikegami, Satoshi Suzuki, Ichiro Yoshimura, Tomohiko Asano & Masamichi Hayakawa

  2. Department of Parasitology and Immunology, National Defense Medical College, 3-2, Namiki, Tokorozawa, 359-8513, Saitama, Japan

    Takushi Tadakuma & Takeshi Ono

  3. Department of Public health, National Defense Medical College, Japan

    Kazuo Yamakami

Authors
  1. Shusei Ikegami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takushi Tadakuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuo Yamakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ichiro Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomohiko Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masamichi Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takushi Tadakuma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ikegami, S., Tadakuma, T., Yamakami, K. et al. Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen. Hum Cell 18, 17–23 (2005). https://doi.org/10.1111/j.1749-0774.2005.tb00053.x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1749-0774.2005.tb00053.x

Key words

Search

Navigation